Dr. Helena Chang, Director of the Revlon/UCLA Breast Center, received an award by the Entertainment Industry Foundation (EIF) and the Women's Cancer Research Fund (WCRF) in support of a pilot study to determine whether structured exercise intervention can become an effective modality in managing breast cancer. The study aims to determine the feasibility of incorporating exercise into the patient’s cancer treatment and to understand the effects of exercise on breast cancer survival. Since 2006, the EIF/WCRF has funded more than one million dollars in support of Dr. Chang's research and the care provided to women at the Revlon/UCLA Breast Center. The awards have greatly enhanced our quest to understand breast cancer and improve the services available to women with breast cancer.
The Barbara/Fred Kort Fund has provided a generous fund to start projects in dissecting the biology of triple negative breast cancer.
The Kolokotrones Fund has provided the Revlon/UCLA Breast Center long-term support to study drug resistance in triple-negative breast cancer. The research fund has allowed us to uncover breast cancer stem cell biomarkers that predict tumor responses to different drugs and drug combinations. The fund has also enabled us to discover the molecules that modulate these biomarkers’ expressions.
With the support of The Leslie and Susan Gonda (Goldschmied) Foundation, Dr. Helena Chang developed the Clinical Trials Unit (CTU) for Breast Cancer in 1999 in an effort to bring discoveries from the bench to the bedside and back. The CTU manages all on-going clinical research trials at the Revlon/UCLA Breast Center and facilitates the collaboration between the clinic and laboratory. The CTU is responsible for data management and monitoring, developing clinical protocols and overseeing compliance to regulations and reporting findings.
Current projects include: